Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Nammi Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Exscientia AI Limited
Memorial Sloan Kettering Cancer Center
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Zumutor Biologics Inc.
Agenus Inc.
City of Hope Medical Center
Eli Lilly and Company
National Cancer Institute (NCI)
Orano Med LLC
Filamon LTD
PMV Pharmaceuticals, Inc
Washington University School of Medicine
BeOne Medicines
Monte Rosa Therapeutics, Inc
ViroMissile, Inc.
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Duke University
University of Florida
AstraZeneca
Tizona Therapeutics, Inc
Essen Biotech
Essen Biotech
MBrace Therapeutics
Clasp Therapeutics, Inc.
Centre Paul Strauss
Roswell Park Cancer Institute
Institut Bergonié
Daiichi Sankyo
Oscotec Inc.
University of Michigan Rogel Cancer Center
Kidney Cancer Research Bureau
HealthPartners Institute
Institut Bergonié
Second Life Therapeutics
University of Kansas Medical Center
Phrontline Biopharma
Medical College of Wisconsin
Innate Pharma
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Complement Theory Inc.
Tanabe Pharma America, Inc.
RenJi Hospital